Aytu BioPharma Stock Climbs 44% After-Hours: Here's Why
Tanya Rawat 1 day ago
MarketsAfter-Hours CenterEarningsHealth CareEquities
Aytu BioPharma shares surged after hours as investors assessed results and acquisition terms.
Aytu Biopharma Inc (NASDAQ: AYTU) shares jumped 43.96% to $2.62 in after-hours trading on Monday after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceuticals.
Aytu BioPharma is focused on developing and commercializing prescription medicines for central nervous system conditions, including major depressive disorder (MDD) and attention-deficit/hyperactivity disorder (ADHD).
Aytu BioPharma Reports Fiscal 2027 First-Quarter Results
Aytu reported first-quarter revenue of $14.84 million, up 6.9% year over year from $13.89 million. Revenue topped the analyst estimate of $13.52 million by approximately 9.8%.
The earnings data provided lists a loss of $0.20 per share, compared with the analyst estimate of a $0.16 loss, representing a 25% miss. Aytu’s release identifies the $0.20 loss as GAAP basic and diluted earnings per share.
Net loss was $3.9 million, compared with net income of $2 million in the year-ago quarter. The prior-year period included a $3.8 million non-cash gain related to derivative warrant liabilities, compared with a $276,000 gain in the latest quarter. Adjusted EBITDA loss widened to $2.6 million from $587,000.
EXXUA Revenue and Prescriptions Increase
EXXUA, Aytu’s treatment for major depressive disorder in adults, generated $4.9 million in net revenue, up 24.5% sequentially from the fourth quarter of fiscal 2026. Total prescriptions increased 32.5% sequentially to 4,400.
CEO Josh Disbrow said the quarter’s performance was driven by EXXUA growth, adding that the company looks forward to continuing to support patients living with major depressive disorder.
The ADHD portfolio generated $7.7 million in revenue, down from $13.2 million a year earlier, primarily reflecting reduced promotional emphasis and generic competition. Pediatric portfolio revenue increased to $2.2 million from $0.7 million.
Rosemont Pharmaceuticals to Acquire Aytu for $2.70 Per Share
Separately, Aytu announced a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings Inc. in an all-cash transaction valued at approximately $56 million on a fully diluted basis.
Rosemont will offer $2.70 per Aytu share, representing a 41.1% premium to the company’s 30-day volume-weighted average share price. Aytu’s board of directors unanimously approved the transaction.
Closing is expected by the end of 2026, subject to customary conditions, including the tender of shares representing at least a majority of Aytu’s outstanding common stock. Aytu will not hold an earnings conference call to discuss its quarterly results because of the pending merger.
Trading Metrics, Technical Analysis
Aytu BioPharma has a market capitalization of approximately $19.78 million.
Over the past year, Aytu BioPharma shares have fallen 8.08%.
The stock has traded between a 52-week high of $3.07 and a low of $1.75.
Benzinga’s Edge Stock Rankings show a negative price trend across short-, medium- and long-term time frames.

Price Action: AYTU shares closed regular trading at $1.82 on Monday, up 2.25%.
See More: Top Momentum Stocks
Photo Courtesy: Elpisterra on Shutterstock.com
